drugset / Trial / NCT00513435
Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying the how well saracatinib works in treating patients with metastatic or recurrent head and neck cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Timeline
- Start
- 2007-07
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | saracatinib | Small molecule | — | Oral |